secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001824293-24-000107
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track
-------------------------------------------------------------------------------

- Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).
- Cash and equivalents $6.4M as of June 30, 2024; public offering in June raised $4.0M gross.
- Cash expected to fund operations into Q1 2025; plans to raise additional funds.
- GRI-0621 Phase 2a IPF biomarker study: interim data Q4 2024, topline data Q1 2025.
- GRI-0803 SLE program progressing preclinically; IND-enabling contingent on funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000107/0001824293-24-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000107/val-20240814.htm
  HTML page:      https://secwatch.observer/filing/0001824293-24-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer